ArticleFrontiers in cellular and infection microbiology2026
Analytical performance evaluation of MAGLUMI HBeAg and anti-HBe chemiluminescence immunoassays and comparison with the Abbott assays.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatitis B e antigen (HBeAg) and its corresponding antibody (anti-HBe) serve as critical serological markers in the evaluation and therapeutic management of Hepatitis B virus (HBV) infection. Study design: This retrospective study was designed to evaluate the performance of the newly CE-marked MAGLUMI HBeAg (CLIA) and MAGLUMI Anti-HBe (CLIA) assays by comparing with Abbott Architect HBeAg and Abbott Architect Anti-HBe assays, respectively. Analytical performance was verified in compliance with the guidelines issued by the Clinical and Laboratory Standards Institute (CLSI). Negative and positive specimens were collected to determine negative percent agreement (NPA) and positive percent agreement (PPA) respectively. Analytical specificity was assessed using negative samples containing potentially cross-reacting substances. Additionally, analytical sensitivity was evaluated using 1st WHO International Standard. Results: The claimed performance specifications for LoB, LoD, linearity, and precision were successfully verified. Both MAGLUMI HBeAg (CLIA) and MAGLUMI Anti-HBe (CLIA) assays exhibited satisfactory NPA and PPA (≥98%). No significant cross-reactivity or interference was observed. Furthermore, all tested plasma matrices demonstrated equivalence to serum in both assays. Conclusions: The MAGLUMI HBeAg (CLIA) and MAGLUMI Anti-HBe (CLIA) met the CLIS verification criteria with favorable analytical performance, and achieved high NPA and PPA relative to the Abbott Architect comparative assays. Besides, future concordance assessments based on a large intended cohort, together with independent clinical validation, are required to fully confirm their suitability for routine clinical application and management of HBV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.